MaxCyte Anticipates Mixed Revenue Outlook for FY25, Projects Decline in Core Revenue

miércoles, 12 de noviembre de 2025, 6:27 pm ET1 min de lectura
MXCT--

MaxCyte Inc (MXCT) expects a potential decline in core revenue for FY25, ranging from 0% to 10%. The SPL Program is expected to contribute approximately $5 million in revenue. Projected cash, cash equivalents, and investments by the end of 2025 are estimated between $152 million and $155 million.

MaxCyte Anticipates Mixed Revenue Outlook for FY25, Projects Decline in Core Revenue

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios